NCT04416568 - Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 14, 2020

Primary Completion Date

November 30, 2025

Study Completion Date

June 30, 2026

Conditions

Malignant Rhabdoid TumorRhabdoid Tumor of the KidneyEpithelioid SarcomaChordoma (Poorly Differentiated or De-differentiated)Atypical Teratoid/Rhabdoid TumorOther INI1 Negative Tumors (With PI Approval)Other SMARCA4-deficient Malignant Tumors (With PI Approval)

Interventions

DRUG

Nivolumab

"Combination Therapy: Nivolumab at predetermined dosage day 1 of a 21-day cycle for 4 cycles.~Monotherapy: Starting with cycle 5 nivolumab at predetermined dosage on day 1 and day 15 of a 28-day cycle"

DRUG

Ipilimumab

Combination Therapy: Ipilimumab at predetermined dosage day 1 of a 21-day cycle for 4 cycles

Trial Locations (8)

19104

Children's Hospital of Philadelphia, Philadelphia

30322

Children's Healthcare of Atlanta-Egleston, Atlanta

30342

Children's Healthcare of Atlanta-Scottish Rite, Atlanta

77030

Texas Children's Hospital, Houston

94158

UCSF Benioff Children's Hospital, San Francisco

02114

Massachusetts General Hospital, Boston

02115

Boston Children's Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

collaborator

Gateway for Cancer Research

OTHER

lead

Dana-Farber Cancer Institute

OTHER